Clinical Trials Browser

Interventional × Has results × MK 2206 × Clear all

NCT01251861 2026-05-29

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Phase 2 Active not recruiting

108 enrolled 16 charts

Prostatic Neoplasms

NCT01306045 2024-10-01

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Phase 2 Completed

647 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

NCT00963547 2024-06-04

MK-2206-015

Phase 1 Terminated

33 enrolled 13 charts

Breast Neoplasms

NCT01307631 2022-02-11

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Phase 2 Completed

37 enrolled 9 charts

Endometrial Adenocarcinoma

NCT01248247 2022-01-12

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

334 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01258998 2020-11-04

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

Phase 2 Completed

60 enrolled 8 charts

DermatologicLymphoidOther hematologic neoplasm

Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT00848718 2019-11-12

MK-2206-003

Phase 1 Completed

77 enrolled 24 charts

Neoplasms

NCT01239342 2019-10-10

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Phase 2 Terminated

43 enrolled 12 charts

Carcinoma, Renal Cell

NCT01802320 2019-09-20

Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Phase 2 Completed

18 enrolled 7 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT01604772 2019-05-01

Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma

Phase 2 Completed

16 enrolled 7 charts

Salivary Gland Neoplasms

NCT00670488 2019-04-01

MK-2206-002

Phase 1 Completed

104 enrolled 28 charts

Neoplasms

NCT01277757 2018-12-19

Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer

Phase 2 Completed

30 enrolled 7 charts

Breast Neoplasms

NCT01253447 2018-08-27

AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2 Completed

19 enrolled 8 charts

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT01243762 2018-08-16

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Phase 1 Terminated

47 enrolled 12 charts

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT01021748 2018-08-07

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

Phase 1 Completed

63 enrolled 17 charts

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT01776008 2018-05-08

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Phase 2 Terminated

16 enrolled 5 charts

Breast Neoplasms

NCT01349933 2017-12-05

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2 Completed

21 enrolled 11 charts

Recurrent Squamous Cell Carcinoma of the Nasopharynx

NCT01481129 2017-09-28

Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Completed

22 enrolled 9 charts

Lymphoma, Large B-Cell, Diffuse

NCT01369849 2017-09-15

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1/2 Completed

15 enrolled 13 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01319539 2017-08-30

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Phase 2 Terminated

12 enrolled 9 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01294306 2016-11-29

MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

Phase 2 Completed

80 enrolled 10 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

NCT01283035 2016-06-24

A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Phase 2 Completed

6 enrolled 7 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01425879 2016-06-17

MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

8 enrolled 8 charts

Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular

NCT01658943 2016-03-09

S1115

Phase 2 Completed

137 enrolled 12 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01169649 2016-02-18

Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

Phase 2 Completed

11 enrolled 6 charts

Neuroendocrine Tumors

NCT01260701 2016-01-18

Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Phase 2 Completed

75 enrolled 9 charts

Gastrointestinal

Stomach Neoplasms

NCT01186705 2015-11-18

Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer

Phase 2 Terminated

1 enrolled 4 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT01239355 2015-10-05

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

Phase 2 Terminated

15 enrolled 6 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT01333475 2015-09-30

MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma

Phase 2 Completed

21 enrolled 11 charts

Gastrointestinal

Colorectal Neoplasms

NCT01519427 2014-06-18

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Phase 2 Terminated

2 enrolled 9 charts

Melanoma

NCT01235897 2014-04-17

MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies

Phase 1 Completed

17 enrolled 7 charts

Neoplasms